US/China-based MicuRx completes $25m Series B round
This article was originally published in Scrip
Executive Summary
Hayward, California-based antibiotics developer MicuRx Pharmaceuticals raised $25 million in a Series B venture capital round to fund a Phase II clinical trial in the US for its next-generation oral oxazolidinone MRX-I, which already is under evaluation in Phase II trials in China.